Meeting
2016 ASCO Annual Meeting
Epigenetic resensitization to platinum in recurrent, platinum-resistant ovarian cancer (OC) using guadecitabine (SGI-110), a novel hypomethylating agent (HMA): Results of a randomized phase 2 study.
Authors
Ursula A. Matulonis
Dana-Farber Cancer Institute, Boston, MA
Ursula A. Matulonis , Amit M. Oza , Angeles Alvarez Secord , Lynda D. Roman , Sarah Patricia Blagden , Susana N. Banerjee , J C Elkas , John J. Nemunaitis , Sharad A. Ghamande , Gini F. Fleming , Merry Jennifer Markham , Hal W. Hirte , Diane M. Provencher , Bristi Basu , Rebecca Sophie Kristeleit , Sue Naim , Yong Hao , Harold N. Keer , Mohammad Azab , Daniela Matei
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gynecologic Cancer
Track
Gynecologic Cancer
Sub Track
Ovarian Cancer
Clinical Trial Registration Number
NCT01696032
Citation
J Clin Oncol 34, 2016 (suppl; abstr 5547)
DOI
10.1200/JCO.2016.34.15_suppl.5547
Abstract #
5547
Poster Bd #
370
Abstract Disclosures
Similar Posters
Poster
2019 ASCO Annual Meeting
Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
First Author: Kathleen N. Moore
Poster
2016 ASCO Annual Meeting
MC1463: Avatar-directed chemotherapy in platinum-resistant ovarian cancer.
First Author: Beverly Long
Poster
2014 ASCO Annual Meeting
Pertuzumab (P) plus chemotherapy (CT) for platinum-resistant ovarian cancer: Safety run-in results of the PENELOPE trial.
First Author: Antonio Gonzalez-Martin
Poster
2014 ASCO Annual Meeting
Phase II trial of oxaliplatin and 5-FU in patients (pts) with platinum-resistant recurrent (PRR) ovarian carcinoma (OVCA).
First Author: Joseph N. Kerger